RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06618664, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Unresectable locally advanced or metastatic HCC confirmed by histopathologically/cytologically.

    Inclusion criterion 3

  3. Child-Pugh score of A or B7.

    Inclusion criterion 8

  4. Patients with liver tumor burden greater than 50% of total liver in volume or received liver transplants.

    Exclusion criterion 5

  5. ECOG PS of 0-1.

    Inclusion criterion 7

  6. Active infection, or fever of unknown cause ≥ 38.5℃ in the first 7 days of randomization, or WBC > 15×109/L at baseline.

    Exclusion criterion 13

  7. At least one measurable lesion based on RECIST v1.1 criteria.

    Inclusion criterion 4

  8. Patients with other malignancies currently or within the past 5 years.

    Exclusion criterion 2

    Known positive history of human immunodeficiency virus test or acquired immunodeficiency syndrome, known HBV infection, known HCV infection.

    Exclusion criterion 14

  9. Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception.

    Inclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06618664, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able and willing to provide a written informed consent.
  • ≥ 18 years old, both male and female.
  • Unresectable locally advanced or metastatic HCC confirmed by histopathologically/cytologically.
  • At least one measurable lesion based on RECIST v1.1 criteria.
  • Barcelona clinic liver cancer: Stage B or C.
  • No previous systemic antitumor therapy for HCC.
  • ECOG PS of 0-1.
  • Child-Pugh score of A or B7.
  • Expected survival period ≥ 12 weeks.
  • Adequate organ function.
  • Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception.

Exclusion Criteria:

  • Hepatic cholangiocarcinoma, mixed hepatocellular carcinoma -cholangiocarcinoma, sarcomatoid hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma.
  • Patients with other malignancies currently or within the past 5 years.
  • With known severe allergic reactions to any other monoclonal antibodies.
  • Patients with known CNS metastasis or hepatic encephalopathy.
  • Patients with liver tumor burden greater than 50% of total liver in volume or received liver transplants.
  • Patients with symptomatic ascites or pleural effusion.
  • Patients with hypertension which cannot be well controlled by antihypertensives.
  • Uncontrolled cardiac diseases or symptoms.
  • Known hereditary or acquired bleeding (e.g., coagulopathy) or a tendency to clot (e.g., hemophiliacs).
  • Major vascular disease occurred in the 6 months before randomization.
  • Gastrointestinal perforation or gastrointestinal fistula within 6 months before randomization.
  • Major surgery within 28 days before randomization or expected to require major surgery during the study period.
  • Active infection, or fever of unknown cause ≥ 38.5℃ in the first 7 days of randomization, or WBC > 15×109/L at baseline.
  • Known positive history of human immunodeficiency virus test or acquired immunodeficiency syndrome, known HBV infection, known HCV infection.
  • Patients who received live vaccines within 28 days before randomization, or are expected to be vaccinated during the treatment period
  • Patients with other potential factors that may affect the study results.

Quoted from ClinicalTrials.gov, NCT06618664, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06618664, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06618664